

8. (Amended) [A] The vehicle [according to any one of claims 5-7]claim 5, wherein at least one of said proteins comprises a tissue tropism determining part of a fiber protein derived from a subgroup B adenovirus.

9. (Amended) [A] vehicle [according to]of claim 7 [or claim 8], wherein said subgroup B adenovirus is adenovirus 16.

10. (Amended) [A] The vehicle [according to any one of claims 7 through 9]claim 7, further comprising:
at least one protein derived from an adenovirus not belonging to subgroup B, or a functional part, derivative and/or analogue thereof.

12. (Amended) [A] The vehicle [according to anyone of the claims 1-11]of claim 1 characterized by comprising nucleic acid derived from an adenovirus.

13. (Amended) [A] The vehicle [according to anyone of the claims 1-12]of claim 1, comprising nucleic acid derived from at least two different adenoviruses.

14. (Amended) [A] vehicle [according to]of claim 12 [or claim 13], wherein said nucleic acid at least encodes a fiber protein comprising at least a tissue tropism determining part of a subgroup B adenovirus fiber protein, in particular of a serotype 11, 16, 35 and/or 51, preferably of adenovirus 16 or a functional derivative and/or analogue thereof.

15. (Amended) [A] The vehicle [according anyone of claims 12-14]of claim 12, wherein said adenovirus nucleic acid is a modified nucleic acid such that the capacity of said adenovirus nucleic acid to replicate in a target cell has been reduced or disabled, preferably through a deletion of at least part of the E1-region.

At

16. (Amended) [A] The vehicle [according to anyone of the claims 12-15] of claim 12, wherein said adenovirus nucleic acid is a modified nucleic acid such that the capacity of a host immune system to mount an immune response against adenovirus proteins encoded by said adenovirus nucleic acid has been reduced or disabled[, preferably through a deletion of E2A and/or at least part of the E4-region].

Sub P2

17. (Amended) [A] The vehicle [according to anyone of claims 1-16] of claim 1, comprising a minimal adenovirus vector or an Ad/AAV chimaeric vector.

Sub P2

18. (Amended) [A] The vehicle [according to anyone of claims 1-17] of claim 1, further comprising at least one nucleic acid of interest.

Sub P2

19. (Amended) [A] The vehicle [according to anyone of claims 1-18] of claim 1, wherein said vehicle is a subgroup B adenovirus capsid comprising at least one nucleic acid of interest.

Sub P2

22. (Amended) The vehicle of [any one of claims 19-21] of claim 19, wherein said subgroup B adenovirus is adenovirus 16.

Sub P2

23. (Amended) A method for producing a vehicle [according to any one of claims 1-22] having at least a tissue tropism for fibroblast-like or macrophage-like cells, said method comprising providing a cell with means for the assembly of said vehicle wherein said means includes a means for the production of an adenovirus fiber protein, wherein said fiber protein comprises at least a tissue tropism determining part of a subgroup B adenovirus, in particular a serotype 11, 16, 35 and/or 51 adenovirus fiber protein or a functional derivative and/or analogue thereof.

Sub P2

24. (Amended) A cell for producing a vehicle [according to any one of claims 1-22] having at least a tissue tropism for fibroblast-like or macrophage-like cells, said cell comprising: means for the assembly of said vehicle wherein said means includes a means for the production of an adenovirus fiber protein, said fiber protein comprising at least a tissue tropism determining part of a subgroup B adenovirus fiber protein.